Fate Therapeutics Inc [NASDAQ: FATE] loss -5.02% or -0.24 points to close at $4.54 with a heavy trading volume of 4022303 shares. The daily chart for FATE points out that the company has recorded 127.00% gains over the past six months. If we look at
Fate Therapeutics Inc [NASDAQ: FATE] loss -4.36% or -0.23 points to close at $5.04 with a heavy trading volume of 2329095 shares. The daily chart for FATE points out that the company has recorded 149.50% gains over the past six months. If we look at
Fate Therapeutics Inc [NASDAQ: FATE] jumped around 0.37 points on Thursday, while shares priced at $8.35 at the close of the session, up 4.64%. The company report on March 5, 2024 at 4:01 PM that Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing
Fate Therapeutics Inc [NASDAQ: FATE] gained 7.34% or 0.51 points to close at $7.46 with a heavy trading volume of 4110344 shares. The company report on February 26, 2024 at 4:01 PM that Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and
Fate Therapeutics Inc [NASDAQ: FATE] stock went on an upward path that rose over 9.09% on Thursday, amounting to a one-week price increase of more than 15.88%. The company report on February 15, 2024 at 8:00 AM that Fate Therapeutics to Webcast Conference Call Reporting
Fate Therapeutics Inc [NASDAQ: FATE] stock went on an upward path that rose over 9.89% on Thursday, amounting to a one-week price decrease of less than -9.62%. The company report on February 2, 2024 at 4:01 PM that Fate Therapeutics Reports New Employee Inducement Awards
Fate Therapeutics Inc [NASDAQ: FATE] jumped around 1.16 points on Monday, while shares priced at $5.72 at the close of the session, up 25.44%. The company report on January 8, 2024 at 8:00 AM that Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for
Fate Therapeutics Inc [NASDAQ: FATE] loss -4.55% or -0.22 points to close at $4.61 with a heavy trading volume of 3121648 shares. The company report on January 8, 2024 at 8:00 AM that Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 /
© 2024, Powered by Smart TechOne
